• High-risk MDS, AML: Phase I/II (active, not recruiting-NCT01451268)• Metastatic thyroid cancer: Phase II (completed- NCT01013597)• Refractory prostate cancer: Phase II (completed- NCT00667862)• Refractory colorectal cancer: Phase II (completed-NCT00690677)• Refractory CML: Phase II/III (completed- NCT00449761)• HER2-negative locally recurrent or metastatic breast cancer: Phase II (completed- NCT00777049). This evidence concerns the gene ERBB2 and thyroid gland carcinoma.